Curis has started dosing patients in a Phase l trial of CA-4948 to treat patients with lymphoma.
CA-4948 is an orally available small molecule inhibitor of IRAK4 kinase, and the second licensed programme from a partnership between Curis and Aurigene to enter the clinic.
Go deeper with GlobalData
The Phase l trial seeks to assess the safety, tolerability, and pharmacokinetic profile of CA-4948.
It also aims to identify any dose-limiting toxicities and establish the recommended Phase ll dose for treatment of patients with lymphomas.
The trial’s dose escalation stage will enrol patients with relapsed/refractory non-Hodgkin’s lymphoma, while the expansion stage will focus on specific populations of patients with lymphomas harbouring alterations in the MYD88 gene or toll-like receptor (TLR) signalling pathway.
Curis president and CEO Ali Fattaey said: “Given the prevalence of activating mutations in the MYD88 gene and the TLR pathway, IRAK4 represents a significant target for the precision treatment of patients with different hematologic malignancies.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData“In addition to its preclinical anti-tumor activity in MYD88-mutated lymphomas, we have observed encouraging effects of CA-4948 in animal models of acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) as well as non-oncology inflammatory disease models.”
In addition, Curis has partnered with Aurigene to collaborate in the fields of immuno-oncology and precision oncology.
